Macquarie Group
MLNT

Macquarie Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Macquarie Group’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,240
Closed -$5K – 2265
2018
Q4 		$5K Buy
+1,240
New +$15.9K ﹤0.01% 2118
2018
Q1 		– Sell
-5
Closed – – 2497
2017
Q4 		$0 Buy
+5
New +$370 ﹤0.01% 2482

Other funds holding MLNT

IP
Isthmus Partners Madison, Wisconsin $953M AUM 18.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ZIM
Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group's MLNT Position: Q1 2019 in Review

Macquarie Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2019, closing a stake of 1,240 shares — an estimated $5K sold.

Macquarie Group first reported a position in MLNT in Q4 2017 and held it in 2 quarters. The position peaked at $5K in Q4 2018. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

  • Macquarie Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 1,240 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $5K.
  • Macquarie Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Macquarie Group's Melinta Therapeutics, Inc. Common Stock position peaked at $5K in Q4 2018.
  • 52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.